Kangzhe Pharmaceutical announced that the innovative drug CMS-D001, a highly selective TYK2 inhibitor independently developed by Demei Pharmaceutical, a subsidiary of the Group, has previously been approved to carry out clinical trials with multiple indicated drugs. On September 11, 2026, CMS-D001 obtained the clinical trial approval notice for systemic lupus erythematosus indicated by the NMPA and received it on September 14, 2026; the Group is actively preparing to carry out related clinical trials.

Zhitongcaijing · 3d ago
Kangzhe Pharmaceutical announced that the innovative drug CMS-D001, a highly selective TYK2 inhibitor independently developed by Demei Pharmaceutical, a subsidiary of the Group, has previously been approved to carry out clinical trials with multiple indicated drugs. On September 11, 2026, CMS-D001 obtained the clinical trial approval notice for systemic lupus erythematosus indicated by the NMPA and received it on September 14, 2026; the Group is actively preparing to carry out related clinical trials.